Proteomics Exploration of Brucella melitensis to Design an Innovative Multi-Epitope mRNA Vaccine.

Autor: Asadinezhad M; Students Research Committee, Ilam University of Medical Sciences, Ilam, Iran.; Department of Microbiology, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran., Pakzad I; Department of Microbiology, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran.; Clinical Microbiology Research Center, Ilam University of Medical Sciences, Ilam, Iran., Asadollahi P; Department of Microbiology, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran.; Clinical Microbiology Research Center, Ilam University of Medical Sciences, Ilam, Iran., Ghafourian S; Department of Microbiology, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran.; Clinical Microbiology Research Center, Ilam University of Medical Sciences, Ilam, Iran., Kalani BS; Department of Microbiology, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran.; Clinical Microbiology Research Center, Ilam University of Medical Sciences, Ilam, Iran.; Department of Medical Microbiology, School of Medicine, Ilam University of Medical Sciences, Ilam, Iran.
Jazyk: angličtina
Zdroj: Bioinformatics and biology insights [Bioinform Biol Insights] 2024 Aug 30; Vol. 18, pp. 11779322241272404. Date of Electronic Publication: 2024 Aug 30 (Print Publication: 2024).
DOI: 10.1177/11779322241272404
Abstrakt: Brucellosis is a chronic and debilitating disease in humans, causing great economic losses in the livestock industry. Making an effective vaccine is one of the most important concerns for this disease. The new mRNA vaccine technology due to its accuracy and high efficiency has given promising results in various diseases. The objective of this research was to create a novel mRNA vaccine with multiple epitopes targeting Brucella melitensis . Seventeen antigenic proteins and their appropriate epitopes were selected with immunoinformatic tools and surveyed in terms of toxicity, allergenicity, and homology. Then, their presentation and identification by MHC cells and other immune cells were checked with valid tools such as molecular docking, and a multi-epitope protein was modeled, and after optimization, mRNA was analyzed in terms of structure and stability. Ultimately, the immune system's reaction to this novel vaccine was evaluated and the results disclosed that the designed mRNA construct can be an effective and promising vaccine that requires laboratory and clinical trials.
Competing Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
(© The Author(s) 2024.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje